Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Staar Surgical CoFRA:SR3 +0.74%79 Forward PE Ratio is 84.90 as of Aug. 16, 2026. GuruFocus rates FRA:SR3 with a GF Score™ of 79/100 and a GF Value™ of €30.06 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 390 Medical Devices & Instruments companies, Staar Surgical Co ranks worse than 91.54% on this metric.
Staar Surgical Co (FRA:SR3) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Staar Surgical Co Forward PE Ratio Related Terms
Staar Surgical Co Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Staar Surgical Co's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Staar Surgical Co Forward PE Ratio Chart
Staar Surgical Co Annual Data
Trend
2016-12
2018-12
2019-12
2020-12
2021-12
2022-12
2023-12
2024-12
2025-12
Forward PE Ratio
212.77
73.53
81.97
144.93
99.01
39.37
42.92
30.47
435.11
Staar Surgical Co Quarterly Data
2016-09
2016-12
2017-03
2018-06
2018-09
2018-12
2019-03
2019-06
2019-09
2019-12
2020-03
2020-06
2020-09
2020-12
2021-03
2021-06
2021-09
2021-12
2022-03
2022-06
2022-09
2022-12
2023-03
2023-06
2023-09
2023-12
2024-03
2024-06
2024-09
2024-12
2025-12
2026-03
2026-06
Forward PE Ratio
200.00
212.77
625.00
357.14
227.27
73.53
117.65
90.91
62.89
81.97
70.42
243.90
82.64
144.93
294.12
555.56
166.67
99.01
90.09
88.50
60.24
39.37
69.93
65.79
49.75
42.92
136.99
142.86
666.67
30.47
435.11
497.66
88.93
FRA:SR3 vs KMTS, AZTA, BLFS: Forward PE Ratio Comparison
For the Medical Instruments & Supplies subindustry, Staar Surgical Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Staar Surgical Co Forward PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Staar Surgical Co's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Staar Surgical Co's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Staar Surgical Co (FRA:SR3) has a Forward PE Ratio of 84.90 as of Aug. 16, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Staar Surgical Co and its competitors. According to the industry distribution chart, Staar Surgical Co ranks #357 out of 390 companies in the Medical Devices & Instruments industry, placing it in the top 91.5%.
Is Staar Surgical Co's Forward PE Ratio too high?
Staar Surgical Co's current Forward PE Ratio is 84.90. The Medical Devices & Instruments industry median Forward PE Ratio is 20.34. Staar Surgical Co's value of 84.90 is 317.4% above this industry median. Based on the distribution chart, Staar Surgical Co ranks #357 out of 390 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Staar Surgical Co has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Staar Surgical Co's Forward PE Ratio compare to KMTS and AZTA?
According to the Medical Devices & Instruments industry distribution chart, Staar Surgical Co ranks #357 out of 390 companies for Forward PE Ratio. This places Staar Surgical Co in the lower half of its industry. The industry median Forward PE Ratio is 20.34. Staar Surgical Co's value of 84.90 is 317.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 20.34, based on 390 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Staar Surgical Co's current Forward PE Ratio of 84.90 is 317.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Staar Surgical Co and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 20.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Staar Surgical Co's current Forward PE Ratio is 84.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Staar Surgical Co stock overvalued right now?
Based on GuruFocus' analysis, Staar Surgical Co (FRA:SR3) is currently considered Modestly Undervalued. The stock's GF Value™ is €30.06, compared to a current price of €21.81 — trading 27.4% below its estimated fair value. The current Forward PE Ratio is 84.90 and 317.4% above the Medical Devices & Instruments industry median of 20.34. Staar Surgical Co's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Staar Surgical Co (FRA:SR3), the current Forward PE Ratio is 84.90 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Staar Surgical Co (FRA:SR3) Overvalued in 2026?
Based on GuruFocus' analysis, Staar Surgical Co stock appears to be undervalued.
The current stock price of €21.81 is trading 27.4% below its estimated GF Value™ of €30.06.
GuruFocus considers Staar Surgical Co to be Modestly Undervalued.
Key valuation signals for FRA:SR3:
Forward PE Ratio: 84.90
GF Value™: €30.06 vs. price of €21.81 (27.4% below fair value)
Industry Position: 317.4% above the Medical Devices & Instruments median (#357 of 390)
No single metric tells the full story. See the FRA:SR3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.
79GF Score
Get the complete analysis for FRA:SR3
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:SR3 has been successfully added to your 
